









Markets
/
Stocks
/
nasdaq-cgtx
/

Cognition Therapeutics Inc

CGTX

1.570USD

-0.070-4.27%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

101.99MMarket Cap

LossP/E TTM



Cognition Therapeutics Inc

1.570

-0.070-4.27%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Cognition Therapeutics Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cognition Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

253 / 501

Overall Ranking

456 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

3.250

Target Price

+98.17%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Cognition Therapeutics Inc Highlights

StrengthsRisks

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate CT1812 in clinical programs in Alzheimer's disease, dementia with Lewy bodies and dry age-related macular degeneration (dry AMD). Its lead product candidate, CT1812, is an investigational orally delivered, small molecule modulator that penetrates the blood-brain and blood-retina barriers and binds selectively to the sigma-2 receptor (S2R) complex; and through its modulation of S2R restores normal function of synapses, as well as critical cellular processes such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling, lipid membrane-bound protein trafficking and receptor stabilization at the cell surface. It is developing other product candidates in the area of synucleinopathies.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -2.54, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 11.23M shares, decreasing 29.48% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 96.40K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Cognition Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 6.28, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -2.54, which is -86.96% below the recent high of -0.33 and -89.29% above the recent low of -4.81.

Score

Industry at a Glance

Previous score

6.28

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 253/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Cognition Therapeutics Inc is 3.50, with a high of 4.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

3.250

Target Price

+98.17%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Cognition Therapeutics Inc

CGTX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 7.18, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 2.06 and the support level at 1.29, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.75

Change

-1.57

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.025

Sell

RSI(14)

44.620

Neutral

STOCH(KDJ)(9,3,3)

26.755

Neutral

ATR(14)

0.141

Low Volatility

CCI(14)

-112.413

Sell

Williams %R

91.488

Oversold

TRIX(12,20)

-0.062

Sell

StochRSI(14)

5.549

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.646

Sell

MA10

1.663

Sell

MA20

1.736

Sell

MA50

1.846

Sell

MA100

1.330

Buy

MA200

0.889

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 12.73%, representing a quarter-over-quarter decrease of 29.73%. The largest institutional shareholder is The Vanguard, holding a total of 1.30M shares, representing 1.48% of shares outstanding, with 50.44% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Bios Equity Partners, LP.

6.00M

The Vanguard Group, Inc.

Star Investors

1.30M

+5.26%

Acadian Asset Management LLC

701.94K

-30.33%

Chescapmanager, L.L.C.

503.26K

Voss Capital LLC

450.00K

Geode Capital Management, L.L.C.

368.72K

-0.07%

CM Management, LLC

250.00K

-37.50%

Ricciardi (Lisa)

218.64K

+30.89%

American Financial Group, Inc.

205.00K

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 1.19. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.